Iranian Journal of Pediatrics

Published by: Kowsar

Experience of a Single Center in NTBC Use in Management of Hereditary Tyrosinemia Type I in Libya

Hanna Alobaidy 1 , * and Emna Barkaoui 2
Authors Information
1 Department of Pediatrics, Faculty of Medicine, Elkhadra Hospital, Tripoli University, Tripoli, Libya
2 Pasteur Institute, Children’s Hospital, Tunis, Tunisia
Article information
  • Iranian Journal of Pediatrics: October 28, 2015, 25 (5); e3608
  • Published Online: October 6, 2015
  • Article Type: Research Article
  • Received: June 22, 2015
  • Accepted: August 16, 2015
  • DOI: 10.5812/ijp.3608

To Cite: Alobaidy H, Barkaoui E. Experience of a Single Center in NTBC Use in Management of Hereditary Tyrosinemia Type I in Libya, Iran J Pediatr. 2015 ; 25(5):e3608. doi: 10.5812/ijp.3608.

Abstract
Copyright © 2015, Growth & Development Research Center.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
References
  • 1. Paradis K. Tyrosinemia: the Quebec experience. Clin Invest Med. 1996; 19(5): 311-6[PubMed]
  • 2. van Spronsen FJ, Thomasse Y, Smit GP, Leonard JV, Clayton PT, Fidler V, et al. Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology. 1994; 20(5): 1187-91[PubMed]
  • 3. van Spronsen FJ, Smit GP, Wijburg FA, Thomasse Y, Visser G, Heymans HS. Tyrosinaemia type I: considerations of treatment strategy and experiences with risk assessment, diet and transplantation. J Inherit Metab Dis. 1995; 18(2): 111-4[PubMed]
  • 4. Russo PA, Mitchell GA, Tanguay RM. Tyrosinemia: a review. Pediatr Dev Pathol. 2001; 4(3): 212-21[PubMed]
  • 5. Masurel-Paulet A, Poggi-Bach J, Rolland MO, Bernard O, Guffon N, Dobbelaere D, et al. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis. 2008; 31(1): 81-7[DOI][PubMed]
  • 6. Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet. 1992; 340(8823): 813-7[PubMed]
  • 7. Schiff M, Broue P, Chabrol B, De Laet C, Habes D, Mention K, et al. Heterogeneity of follow-up procedures in French and Belgian patients with treated hereditary tyrosinemia type 1: results of a questionnaire and proposed guidelines. J Inherit Metab Dis. 2012; 35(5): 823-9[DOI][PubMed]
  • 8. El-Karaksy H, Rashed M, El-Sayed R, El-Raziky M, El-Koofy N, El-Hawary M, et al. Clinical practice. NTBC therapy for tyrosinemia type 1: how much is enough? Eur J Pediatr. 2010; 169(6): 689-93[DOI][PubMed]
  • 9. Schlune A, Thimm E, Herebian D, Spiekerkoetter U. Single dose NTBC-treatment of hereditary tyrosinemia type I. J Inherit Metab Dis. 2012; 35(5): 831-6[DOI][PubMed]
  • 10. Thimm E, Richter-Werkle R, Kamp G, Molke B, Herebian D, Klee D, et al. Neurocognitive outcome in patients with hypertyrosinemia type I after long-term treatment with NTBC. J Inherit Metab Dis. 2012; 35(2): 263-8[DOI][PubMed]
  • 11. Ben-Omran T. Genetic disorders Among Arab Populations. 2010; : 443-54[DOI]
  • 12. Alobaidy H, Keasta M, Elhoni K. Clinical and biochemical analysis with new advance in management. Jamahiriya Med J. 2004; 3: 37-41
  • 13. Alobaidy H, Yahya N, Said R. Tyrosinemia type I. Clinical and biochemical analysis of cases with poor treatment outcome. Jordan Med J. 2011; 45: 205-11
  • 14. Santra S, Preece MA, Hulton SA, McKiernan PJ. Renal tubular function in children with tyrosinaemia type I treated with nitisinone. J Inherit Metab Dis. 2008; 31(3): 399-402[DOI][PubMed]
  • 15. Ahmad S, Teckman JH, Lueder GT. Corneal opacities associated with NTBC treatment. Am J Ophthalmol. 2002; 134(2): 266-8[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments